2021 New Mexico Statutes
Article 1 - General Provisions
Section 26-1-16.1 - Opioids; requiring practitioners to obtain and review reports from the prescription monitoring program.

A. For purposes of this section:
(1) "opioid" means the class of drugs that includes the natural derivatives of opium, which are morphine and codeine, and related synthetic and semi-synthetic compounds that act upon opioid receptors;
(2) "practitioner" does not include a pharmacist, veterinarian or euthanasia technician;
(3) "prescription monitoring program" means a program that includes a centralized system to collect, monitor and analyze electronically, for Schedule II through V controlled substances, prescribing and dispensing data submitted by dispensers; and
(4) "Schedule II through V controlled substance" means a substance listed in Schedule II, III, IV or V pursuant to the Controlled Substances Act [Chapter 30, Article 31 NMSA 1978] or the federal controlled substances regulation, pursuant to 21 U.S.C. 812.
B. Before a practitioner prescribes or dispenses an opioid for the first time to a patient, the practitioner shall obtain and review a report from the state's prescription monitoring program for such patient for the previous twelve calendar months. If the practitioner has access to a similar report from an adjacent state for the patient, the practitioner shall also obtain and review that report. The provisions of this subsection shall not apply to the prescription or dispensing of an opioid for a supply of four days or less.
C. A practitioner shall obtain and review a report from the state's prescription monitoring program and similar reports from an adjacent state, if any, no less than once every three months for each established patient for whom the practitioner continuously prescribes or dispenses opioids.
D. A practitioner shall document the receipt and review of reports required by this section in the patient's medical record.
E. Nothing in this section shall be construed to prevent a practitioner from obtaining and reviewing a report regarding a practitioner's patient from the state's prescription monitoring program or a similar report from another state with greater frequency than that required by this section, in accordance with the practitioner's professional judgment.
F. Nothing in this section shall be construed to require a practitioner to obtain a prescription monitoring report when prescribing an opioid to a patient in a nursing facility or in hospice care.
G. The professional licensing board of each category of practitioner that is licensed or otherwise authorized to prescribe or dispense an opioid shall promulgate rules to implement the provisions of this section. Nothing in this section shall be construed to prevent a professional licensing board from requiring by rule that practitioners obtain prescription monitoring program reports with greater frequency than that required by this section.
History: Laws 2016, ch. 46, § 1.
Effective dates. — Laws 2016, ch. 46, § 2 makes Laws 2016, ch. 46, § 1 effective January 1, 2017.

Structure 2021 New Mexico Statutes

2021 New Mexico Statutes

Chapter 26 - Drugs and Cosmetics

Article 1 - General Provisions

Section 26-1-1 - Short title.

Section 26-1-2 - Definitions.

Section 26-1-3 - Prohibited acts.

Section 26-1-3.1 - Repealed.

Section 26-1-3.2 - Prescription drug donation.

Section 26-1-4 - Power to enjoin violations.

Section 26-1-5 - Penalty; exemptions.

Section 26-1-6 - Detection of drugs, devices or cosmetic believed adulterated, misbranded or counterfeit; condemnation; destruction or correction of defect; forfeiture and sale.

Section 26-1-7 - Attorney general or district attorney to institute prosecutions.

Section 26-1-8 - Minor violations of act; warnings authorized.

Section 26-1-9 - Addition of poisonous or deleterious substances; color additives.

Section 26-1-10 - Drug or device adulteration.

Section 26-1-11 - Drug or device; misbranding.

Section 26-1-12 - False advertising.

Section 26-1-13 - Packaging and labeling requirements; proprietary preparations.

Section 26-1-14 - New drugs and devices; prerequisites to sale, delivery or giving away; exceptions.

Section 26-1-15 - Dangerous drugs; veterinary use; limitations.

Section 26-1-16 - Dangerous drugs; conditions for sale; prescription refilling; limitations.

Section 26-1-16.1 - Opioids; requiring practitioners to obtain and review reports from the prescription monitoring program.

Section 26-1-17 - Testing laboratory.

Section 26-1-18 - Promulgating regulations; procedure.

Section 26-1-18.1 - Prescription drug prior authorization protocols.

Section 26-1-19 - Power to make inspections and secure samples.

Section 26-1-20 - Personnel.

Section 26-1-21 - Power of board to publish reports and disseminate information.

Section 26-1-22 - Unlawful means of obtaining dangerous drugs enumerated.

Section 26-1-23 - False statements; false pretenses; forgery of labels or prescriptions prohibited.

Section 26-1-24 - Cosmetics; misbranding.

Section 26-1-25 - Cosmetics; adulteration.

Section 26-1-26 - Penalties.